参考文献/References:
[1]葛均波,徐永健.内科学[M].8版.北京:人民卫生出版社,2014.
[2]李立新,姚文明.心力衰竭药物治疗历史现状与未来[J].中国实用内科杂志,2014,34(7):641-643.
[3]杨佳汇,张静.沙库巴曲缬沙坦在心力衰竭中的治疗进展[J].心血管病学进展,2019,40(3):409-412.
[4]Volpe M. Natriuretic peptides and cardio-renal disease[J].Int J Cardiol,2014,176(3):630-639.
[5]Schulz WW, Hagler HK, Buja LM, et al.Ultrastructural localization of angiotensin I-converting enzyme (EC 3.4.15.1) and neutral metalloendopeptidase (EC 3.4.24.11) in the proximal tubule of the human kidney[J].Lab Invest,1988,59(6):789-797.
[6]Vaduganathan M, Desai AS. Angiotensin-neprilysin inhibition as a paradigm for all?[J].Curr Cardiol Rep,2016,18(11): 115.
[7]McMurray JJ,Packer M,Desai AS, et al. for the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med,2014,371(11): 993-1004.
[8]Desai AS,McMurray JJ,Packer M, et al. Effect of the angiotensin receptor neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients[J].Eur Heart J,2015,36(30):1990-1997.
[9]Packer M,McMurray JJ,Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure[J].Circulation,2015,131(1): 54-61.
[10]Parisi C,de Giusti M,Castello L, et al.Sacubitril/valsartan: preliminary experience in post-acute stabilized patients with reduced ejection fraction heart failure[J].Curr Med Res Opin,2019,(35):17-20.
[11]Velazquez?EJ,?Morrow?DA,deVore?AD,et al.Angiotensin-neprilysin inhibition in acute decompensated heart failure[J].N Engl J Med,2019,380(6):539-548.
[12]Velazquez EJ,Morrow DA,deVore AD,et al.Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial[J].Am?Heart?J,2018,(198):145-151.
[13]de Diego C, González-Torres L, Nú?ez JM, et al.Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices[J]. Heart Rhythm,2018,15(3):395-402.
[14] Zile?MR,?O’Meara?E,?Claggett?B, et al Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patientswith HFrEF[J]. J Am Coll Cardiol,2019,73(7):795-806.
[15]Pfau D,Thorn SL,Zhang J,et al.Angiotensin receptor neprilysin inhibitor attenuates myocardial remodeling and improves infarct perfusion in experimental heart failure[J].Sci Rep,2019,9(1):5791.
[16]de Vecchis?R,?Ariano?C,di Biase?G,et al.Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction:a?retrospective cohort study[J]. Herz,2019,44(5):425-432.
[17]Desai?AS,?Vardeny?O,?Claggett?B,et al.Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril:a secondary analysis of the PARADIGM-HF trial[J].JAMA Cardiol,2017,2(1):79-85.
[18]Troncone L, Luciani M, Coggins M, et al.Aβ amyloid pathology affects the hearts of patients with Alzheimer’s disease: mind the heart[J]. J Am Coll Cardiol,2016,68(22):2395 -2407.
[19]Fournier A, Messerli FH, Achard JM, et al.Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials[J]. J Am Coll Cardiol,2004,43(8):1343-1347.
[20] Yancy CW,Jessup M,Bozkurt B,et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. J Am Coll Cardiol,2016,68(13):1476-1488.
[21] King JB, Shah RU, Bress AP, et al.Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction[J].JACC Heart Failure,2016,4(5):392-402.
[22]?Seferovic?JP,?Claggett?B,Seidelmann?SB,et al.Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial[J].Lancet Diabetes Endocrinol,2017,5(5):333-340.
[23]Davidson?EP,?Coppey?LJ,?Shevalye?H,et al.Vascular and neural complications in type 2 diabetic rats:improvement by sacubitril/valsartan greater than valsartan alone[J]. Diabetes,2018,67(8):1616-1626.
[24]?Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences[J].?Semin Nephrol,2004,24(5):469-473.
[25]Jing W,Vaziri ND,Nunes A,et al.LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD[J].Am J Transl Res,2017,9(12):5473-5484.
[26]UK HARP-Ⅲ Collaborative Group.Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- Ⅲ-rationale, trial design and baseline data[J].Nephrol Dial Transplant,2017,32(12):2043-2051.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(2):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(2):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(2):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(2):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(2):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(2):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(2):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(2):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(2):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(2):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[11]潘东 罗勇.沙库巴曲缬沙坦在心力衰竭治疗中的研究进展[J].心血管病学进展,2020,(2):114.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.003]
PAN DongLUO Yong.Sacubitril/valsartan in the Treatment of Heart Failure[J].Advances in Cardiovascular Diseases,2020,(2):114.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.003]
[12]程家元 殷跃辉.沙库巴曲缬沙坦在心血管疾病中的临床应用与展望[J].心血管病学进展,2020,(9):914.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.007]
CHENG Jiayuan YIN Yuehui.Clinical Application and Prospect of Sacubitril Valsartan in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(2):914.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.007]
[13]穆耶赛尔·玉苏普 芦颜美 汤宝鹏.沙库巴曲缬沙坦对心力衰竭患者认知功能的影响[J].心血管病学进展,2023,(8):709.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.009]
Muyassar·Yusup,LU Yanmei,TANG Baopeng.Effect of Sacubritil/Valsartan on Cognitive Function in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2023,(2):709.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.009]